<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301312</url>
  </required_header>
  <id_info>
    <org_study_id>14/0276</org_study_id>
    <nct_id>NCT02301312</nct_id>
  </id_info>
  <brief_title>Clinical Study of POSS-PCU Vascular Grafts for Vascular Access</brief_title>
  <official_title>A Clinical Investigation to Assess the Safety and Performance of POSS-PCU Small Diameter Grafts as Conduits in Arteriovenous (AV) Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and performance of a new vascular graft made of POSS-PCU as a
      vascular access conduit for haemodialysis. 30 patients requiring access for dialysis will be
      enrolled and monitored at regular intervals for 18 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency rate</measure>
    <time_frame>18 months</time_frame>
    <description>The primary performance end point of the study is the patency rate of the POSS-PCU graft at the end of the 18 months as measured with US Doppler, which will be compared to the known patency rate for the PTFE graft</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoint of this study is defined as any Serious Adverse Event related to the implantation procedure or device implantation within 30 days of implantation procedure</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patency rate</measure>
    <time_frame>12 months</time_frame>
    <description>Patency rate of POSS-PCU Graft at 2weeks, 3, 6, and 12 months as measured with US Doppler.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary patency rate</measure>
    <time_frame>18 months</time_frame>
    <description>Any surgical or endovascular intervention required to maintain the patency of the grafts up to the 18 month time point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>POSS-PCU graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POSS-PCU vascular graft will be used to create vascular access for dialysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POSS-PCU vascular graft</intervention_name>
    <description>New vascular access graft</description>
    <arm_group_label>POSS-PCU graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects requiring vascular access for haemodialysis

          -  Subjects with no suitable vein.

          -  Subjects aged 18 - 80 years old

          -  Subjects are able to give voluntary, written informed consent to participate in this
             clinical investigation and from whom consent has been obtained

          -  Patients of child bearing potential, who are sexually active, must agree to the use of
             2 highly effective forms of contraception throughout their participation in the study
             and for 6 months after completion of treatment:

               -  Condom with spermicide.

        AND 1 of the following:

          -  Oral contraceptive or hormonal therapy (e.g. hormone implants).

          -  Placement of an intra-uterine device.

        Exclusion Criteria:

          -  Subjects with predicted short-term survival (less than 18 months) or poor prognosis
             (this will be on the discretion of the clinician in charge)

          -  Subjects with left ventricle ejection fraction (LVEF) &lt;20% diagnosed on ECHO either
             pre-procedure or documented within the previous 3 months prior to consent.

          -  Pregnant or lactating

          -  Allergies to any constituents of the graft material

          -  Patients who are infected or colonized with Methicillin Resistant Staphylococcus
             Aureus (MRSA).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nimrita Verma</last_name>
    <phone>020 7679 6159</phone>
    <email>n.verma@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janice Tsui, MD FRCS</last_name>
    <phone>+44 2077940500</phone>
    <phone_ext>33938</phone_ext>
    <email>janice.tsui@ucl.ac.uk</email>
  </overall_contact_backup>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

